Sparta Biomedical Receives FDA Breakthrough Device Designation for Biomimetic Implant
NEWS PROVIDED BY Sparta Biopharma, Inc. DURHAM, N.C., March 17, 2021 /PRNewswire/ — Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the…
Duke spinout with former FDA commissioner on board raises $6M
By Lauren Ohnesorge – Senior Staff Writer, Triangle Business Journal Feb 5, 2021, 11:26am EST A Duke University-born technology firm aimed at connecting hospital data with clinical research is raising millions – and it plans to hire in…
Deep Blue Medical Advances lures $3.44M in equity for hernia repair tech
by Allan Maurer — February 5, 2021 DURHAM — Deep Blue Medical Advances, which received FDA clearance to begin selling its hernia mesh product in August 2020, has increased its equity to $3.44 million, according to a regulatory…
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO
DURHAM, NC, January 10, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PVSRIPO for the treatment of advanced…
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial
Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS), and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191 Demonstrated Longest Durability of Response to 11 months in B-ALL PBCAR0191 with Enhanced Lymphodepletion Resulted in Objective Response Rate (ORR) of 83% (5/6)…
Tellus Therapeutics Awarded NINDS SBIR Funding
$696,000 Phase I award will support drug product formulation and in vivo pharmacokinetic study to enable an IND application for First-in-Neonate clinical trial DURHAM, NC, UNITED STATES, December 7, 2020 /EINPresswire.com/ — Tellus Therapeutics, a…
Tellus Therapeutics Awarded NINDS SBIR Funding
NEWS PROVIDED BY Tellus Therapeutics, Inc. December 07, 2020, 20:19 GMT Preterm Infant in the Neonatal Intensive Care Unit $696,000 Phase I award will support drug product formulation and in vivo pharmacokinetic study to enable…
Basking Biosciences, Inc. Completes $5.4M Seed Financing
Funding to support development of the first reversible thrombolytic therapy for acute ischemic stroke December 07, 2020 08:30 AM Eastern Standard Time COLUMBUS, Ohio–(BUSINESS WIRE)–Basking Biosciences, Inc. (Basking), a privately-held biopharmaceutical company developing a next…
AI Model Uses Retinal Scans to Predict Alzheimer’s Disease
Published November 30, 2020 Sarah Avery 919-660-1306 Email DURHAM, N.C. – A form of artificial intelligence designed to interpret a combination of retinal images was able to successfully identify a group of patients who were…